<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313102</url>
  </required_header>
  <id_info>
    <org_study_id>Samson APJ 2016</org_study_id>
    <nct_id>NCT03313102</nct_id>
  </id_info>
  <brief_title>Study of T Lymphocytes in Patients With Horton Disease</brief_title>
  <acronym>GAMAIT</acronym>
  <official_title>Study of T Lymphocytes in the Mucosa in Giant-cell Arteritis (GCA) - Giant Cell Arteritis and Mucosal Associated Invariant T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. Corticosteroid&#xD;
      therapy is the reference treatment for GCA. This treatment is highly effective but must be&#xD;
      maintained for 12 to 24 months to avoid relapses, which causes the onset of numerous adverse&#xD;
      effects in this elderly population.&#xD;
&#xD;
      Currently clinicians have no way to estimate this risk of relapse during the treatment of&#xD;
      GCA.&#xD;
&#xD;
      Invariant T lymphocytes associated with the mucous membrane (MAIT), whose role in&#xD;
      vasculitides has recently been shown and which produce IL-17 and IFN-γ, two key cytokines in&#xD;
      the pathophysiology of GCA could be implicated in the pathophysiology of GCA and could&#xD;
      constitute a predictive marker of relapse.&#xD;
&#xD;
      Our hypothesis is that blood MAIT are recruited in the artery wall in patients with GCA and&#xD;
      that the number of circulating MAIT in the blood falls and then returns to normal if the&#xD;
      corticoids are effective.&#xD;
&#xD;
      Given that it will be necessary to include a large number of patients to show that the&#xD;
      persistence of a low number of circulating MAIT in patients treated with corticoids is a&#xD;
      predictor of relapse, we propose, as the first step, to carry out a pilot study to obtain&#xD;
      preliminary data on these new markers.&#xD;
&#xD;
      The study is classified as interventional because a lot of blood samples are taken&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the percentage of blood MAIT (CD3+TCRγδ-CD4-Vα7.2+CD161+) among total TL (CD3+) by flow cytometry</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the percentage of blood MAIT (CD3+TCRγδ-CD4-Vα7.2+CD161+) among total TL (CD3+) by flow cytometry</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Horton Disease</condition>
  <arm_group>
    <arm_group_label>Horton disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>sample of 16 blood tubes</description>
    <arm_group_label>Horton disease</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PATIENTS&#xD;
&#xD;
          -  Patients who have provided written consent&#xD;
&#xD;
          -  Patients with national health insurance cover&#xD;
&#xD;
          -  Age &gt; 50 years&#xD;
&#xD;
          -  Patients with Horton disease at the diagnosis, before any treatment.&#xD;
&#xD;
        Horton disease is defined by ACR criteria [7], the diagnosis is made in the presence of 3&#xD;
        of the following 5 criteria:&#xD;
&#xD;
          -  Age at the onset of the disease of 50 years or older&#xD;
&#xD;
          -  Recent-onset localized headache&#xD;
&#xD;
          -  Temporal artery tenderness or decreased temporal artery pulse&#xD;
&#xD;
          -  Erythrocyte sedimentation rate (ESR) greater than 50 mm in the first hour (or CRP&gt;20&#xD;
             mg/L)&#xD;
&#xD;
          -  Positive temporal artery biopsy (TAB) showing vasculitis with infiltration of&#xD;
             mononuclear cells or granulomatous inflammation with or without giant cells.&#xD;
&#xD;
        Control groups:&#xD;
&#xD;
        Control Group 1: Healthy subjects Healthy subjects will be matched for age and sex with&#xD;
        patients. They will be recruited in Dijon only. They will be healthy volunteers recruited&#xD;
        among blood donors, voluntary hospital personnel (nurses, doctors and secretaries) and&#xD;
        patients without an infectious or inflammatory disease, or cancer or auto-immune disease&#xD;
        (CRP&lt;5mg/L) recruited in the departments of investigators at the CHU of Dijon Burgundy.&#xD;
&#xD;
        Control Group 2: (PPR without ACG)&#xD;
&#xD;
          -  Patient with oral consent&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Age &gt; 50 years old&#xD;
&#xD;
          -  Patient with PPR at diagnosis, before corticosteroid treatment&#xD;
&#xD;
          -  No ACG (see protocol definition)&#xD;
&#xD;
        Control Group 3: (active infection)&#xD;
&#xD;
          -  Patient with oral consent&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Age &gt; 50 years old&#xD;
&#xD;
          -  Inflammatory syndrome (CRP &gt; 10 mg/L and fibrinogen&gt; 4 g/L or CRP &gt; 10 mg/L and VS &gt;&#xD;
             30 mm/h) explained by a infectious syndrome defined by the association:&#xD;
&#xD;
          -  a fever ≥ 38°C, hypothermia &lt; 35°C or fever reported by the patient within 72 hours&#xD;
             before inclusion&#xD;
&#xD;
          -  at least 1 associated clinical and/or radiological sign to an organ infection, for&#xD;
             example: pneumopathy, urinary infection, bacterial dermohypodermatitis, infection&#xD;
             digestive (non-exhasutive list)&#xD;
&#xD;
          -  in the absence of an explanation of the inflammatory syndrome by another cause such as&#xD;
             an inflammatory disease or evolutive neoplastic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults under guardianship&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Patients who have been treated with corticosteroids or immunosuppressants in the month&#xD;
             preceding inclusion&#xD;
&#xD;
          -  Patients treated with chemotherapy, immunosuppressants or biotherapy&#xD;
&#xD;
          -  Contra-indication for corticosteroid therapy&#xD;
&#xD;
          -  Weight &lt;41 kg or Hg &lt;7g/l&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maxime SAMSON, MD</last_name>
    <phone>3.80.29.34.32</phone>
    <phone_ext>+33</phone_ext>
    <email>maxime.samson@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime SAMSON, MD</last_name>
      <phone>3 80 29 34 32</phone>
      <phone_ext>+33</phone_ext>
      <email>maxime.samson@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

